Phase II and Phase III Clinical Trials

• CT137 · PDF Bria-ABC晚期转移性III期试验的生活质量（QOL）结局 QOL outcomes in Bria-ABC late stage metastatic phase 3 trial Saranya Chumsri, Chaitali Nangia, Adriana Kahn, Lawrence Negret, Carmen Calfa, Blaise Bayer, Giuseppe Del Priore, Tamar Aghajanian, William Williams, Kelly McCann
• CT138 · PDF 评估GLSI-100（GP2 + GM-CSF）在新辅助及术后辅助抗HER2治疗后残留病灶或高风险pCR乳腺癌患者中疗效和安全性的进行中III期研究（Flamingo-01）开放标签组迟发型超敏免疫应答的初步结果 Preliminary delayed-type-hypersensitivity immune response results from open-label arm of on-going Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01 Snehal S. Patel, Jaye Thompson, F. Joseph Daugherty, Francois-Clement Bidard, William J. Gradishar, Marcus Schmidt, Miguel Martin, Joyce A. O’Shaughnessy, Hope S. Rugo, Cesar A. Santa-Maria, Laura M. Spring, Mothaffar F. Rimawi
• CT139 · PDF 胚系HFE突变预示胸膜间皮瘤对pegargiminase为基础化疗的精氨酸耗竭产生持久应答 Germline HFE mutations predict for durable response to arginine depletion with pegargiminase-based chemotherapy in pleural mesothelioma Peter Wojciech Szlosarek, George Field, Iuliia Pavlyk, Matthew Young, Michael Allen, Josephine Carpentier, Riyaz Shah, Nick Maskell, David Houghton, Amanda Johnston, John Bomalaski, Louise Jones, Michael Sheaff
• CT140 · PDF S2302-PRAGMATICA-LUNG的最终结果：一项在既往接受免疫治疗的IV期或复发性非小细胞肺癌（NSCLC）受试者（pts）中比较ramucirumab联合pembrolizumab（RP）与标准治疗（SOC）的前瞻性随机研究 Final Results from S2302-PRAGMATICA-LUNG: A prospective randomized study of ramucirumab plus pembrolizumab (RP) versus standard of care (SOC) for participants (pts) previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC) Karen L. Reckamp, Mary W. Redman, Konstantin H. Dragnev, Maya Khalil, Brian S. Henick, James Moon, Pasarlai Ahmadzai, Michael LeBlanc, Daniel R. Carrizosa, Paul J. Hesketh, Ellen V. Sigal, Jeff Allen, Andreas N. Saltos, Bryan A. Faller, Roy S. Herbst, Charles D. Blanke, Jhanelle E. Gray
• CT142 · PDF 在维持完整疗效潜力的同时减少spevatamig（一种CLDN18.2xCD47双特异性抗体）引起的恶心和呕吐 Reducing nausea and vomiting while maintaining the full potential for efficacy with spevatamig, a CLDN18.2xCD47 bispecific antibody Michael J. Overman, Harshabad Singh, Alexander I. Spira, Jason T. Henry, Dani Castillo, Nataliya Uboha, Naomi Fei, Nicholas DeVito, Diana Hanna, Grace H. McGregor, Hui Zou, Minghan Wang, Satya (Nanu) Das, Rita Laeufle, Anwaar Saeed
• CT143 · PDF 采用含优化抗CD47臂的双特异性设计解决与抗CD47药物相关的血液学毒性：一项临床概念验证研究 Resolved hematological toxicities associated with anti-CD47 agents using a bispecific design involving an optimized anti-CD47 arm: A clinical proof of concept study Harshabad Singh, Michael J. Overman, Alexander I. Spira, Jason T. Henry, Dani Castillo, Nataliya Uboha, Naomi Fei, Nicholas DeVito, Diana Hanna, Michael J. Chisamore, Grace H. McGregor, Hui Zou, Minghan Wang, Satya (Nanu) Das, Rita Laeufle, Anwaar Saeed
• CT144 · PDF spevatamig（PT886，一种靶向CLDN18.2和CD47的双特异性抗体）在晚期胃肠道癌患者中作为单药或联合治疗的药代动力学 Pharmacokinetics of spevatamig (PT886), a bispecific antibody targeting CLDN18.2 and CD47, in patients with advanced gastrointestinal cancers as monotherapy or combination therapy Anwaar Saeed, Harshabad Singh, Alexander I. Spira, Jason T. Henry, Dani Castillo, Nataliya Uboha, Naomi Fei, Nicholas DeVito, Diana Hanna, Grace H. McGregor, Hui Zou, Minghan Wang, Satya (Nanu) Das, Rita Laeufle, Michael J. Overman
• CT145 · PDF 卡度尼利单抗（一种PD-1/CTLA-4双特异性抗体）联合化疗（chemo）作为晚期胰腺导管腺癌（PDAC）一线治疗的一项II期、多中心、开放标签研究（COMPASSION-26） A phase II, multicenter, open-label study (COMPASSION-26) of cadonilimab, a PD-1/CTLA-4 bispecific antibody,combined with chemotherapy (chemo) as first-line therapy for advanced pancreatic ductal adenocarcinoma (PDAC) Wenming Wu, Xiafei Hong, Qi Xu, Gang Jin, Zhihua Li, He Tian, Heshui Wu, Yiping Mou, Baocai Xing, Dianrong Xiu, Zhifang Yao, Zhongmin Maxwell Wang, Baiyong Li, Yu Xia
• CT146 · PDF 经6周AG诱导治疗后，索凡替尼联合吉西他滨和白蛋白结合型紫杉醇（AG）序贯治疗或单用AG作为局部晚期或转移性胰腺导管腺癌（mPDAC）一线治疗：一项双队列、探索性II期研究 Sequential treatment with surufatinib combined with gemcitabine and nab-paclitaxel (AG) or AG alone as first-line therapy for locally advanced or metastatic pancreatic ductal adenocarcinoma (mPDAC) after 6 weeks of AG induction therapy: A two-cohort, exploratory phase II study Jialin Li, Miaoyan Wei, Nan Du, Si Shi, Jin Xu, XianJun Yu
• CT147 · PDF 高剂量静脉注射抗坏血酸联合化疗作为顺铂不耐受的肌层浸润性膀胱癌患者的新辅助化疗（NAC） High dose intravenous ascorbate with chemotherapy as NAC for muscle invasive cisplatin ineligible bladder cancer patients Qi Chen, John Taylor, Rahul Parikh, Ben Woolbright, Jeanne Drisko
• CT148 · PDF Ga-68-NGUL和Lu-177-DGUL（pocuvotide satetraxetan）在mCRPC中的安全性、剂量学及RP2D确定：一项1/2期研究结果 Safety, dosimetry, and RP2D determination of Ga‑68‑NGUL and Lu‑177‑DGUL (pocuvotide satetraxetan) in mCRPC: Results from a phase 1/2 study Seung-hwan Jeong, Cheol Kwak, Chang Wook Jeong, Sung Kyu Hong, Jae Lyun Lee, Eu Chang Hwang, Kyo Chul Koo, Keon Wook Kang, Gi Jeong Cheon, Minseok Suh
• CT149 · PDF 卡博替尼联合纳武利尤单抗治疗转移性去势抵抗性前列腺癌的一项2期研究（CANOPY）：中期分析 A phase 2 study of cabozantinib and nivolumab in metastatic castration resistant prostate cancer (CANOPY): Interim analysis Justine Panian, Lin Liu, Minya Pu, Emily Pittman, Samuel Pena, Archana Ajmera, Yu-Wei Chen, Christos Kyriakopoulos, Qian Qin, James Michael Randall, Tian Zhang, Joshua Michael Lang, Akash Patnaik, Rana R. McKay
• CT150 CT150 信迪利单抗联合顺铂和白蛋白结合型紫杉醇诱导治疗局部晚期临界可切除食管鳞状细胞癌：一项单臂、前瞻性、2期研究（NEOCRTEC2001） Sintilimab plus cisplatin and nab-paclitaxel induction treatment for locally advanced borderline resectable esophageal squamous cell carcinoma: A single-arm, prospective, phase 2 study (NEOCRTEC2001) Xin Zhang, Jiadi Wu, Deshen Wang, Zhiqiang Wang, Qiaoqiao Li, Chao Ren, Yuhong Li, Hong Yang
• CT151 · PDF CDK4/6抑制剂达尔西利联合mFOLFOX6治疗经治的转移性结直肠癌：一项Simon两阶段II期研究结果 CDK4/6 inhibitor dalpiciclib combined with mFOLFOX6 in pretreated metastatic colorectal cancer: Results from a Simon two-stage phase II study Xiaoyu Xie, Zhaoliang Yu, Ziqin Lin, Weiwei Li, Dianke Chen, Xiaohui Zhai, Yufeng Chen, Xiaojian Wu
• CT152 · PDF 一项评估JS207（一种靶向PD-1和VEGF的双特异性抗体）联合化疗治疗转移性结直肠癌患者的安全性和疗效的II期试验初步结果 Preliminary results from a phase II trial evaluating the safety and efficacy of JS207, a bispecific antibody targeting PD-1 and VEGF, in combination with chemotherapy in patients with metastatic colorectal cancer Yong Gao, Zhiwei Li, Jianwei Yang, Shuqing Jin, Yiyi Yu, Chang Wang, Xiwen Huang, Jingdong Zhang, Yanhong Gu, Shuqin Ni, Yanlai Sun, Shirong Cai, Liang Han, Xinjun Liang, Haichuan Su, Chenxi Wang, Zhenyu Xu, Jing Xu, Chengbo Jia, Jianjun Zou, Lin Shen
• CT153 · PDF pegulicianine荧光引导手术用于检测腹膜表面恶性肿瘤的可行性 Feasibility of pegulicianine fluorescence guided surgery for detection of peritoneal surface malignancies Brian Schlossberg, Julia Kloetzl, Kate Smith, Jorge Ferrer, Jonathan Greer
• CT154 · PDF 新型BRAF抑制剂plixorafenib（FORE8394）在BRAF V600突变晚期结直肠癌（CRC）中的临床活性和安全性 Clinical activity and safety of novel BRAF inhibitor plixorafenib (FORE8394) in BRAF V600-mutated advanced colorectal cancers (CRC) Rona Yaeger, Sunil Sharma, Aparna Parikh, Stacie Peacock Shepherd, Manish Monga, Ping Jiang, Jessica Jang, Michael Paz, Frank Tsai, Ulka Vaishampayan, Jordi Rodon
• CT155 · PDF NG-350A（一种表达CD40激动性抗体的腺病毒载体）联合放化疗（CRT）治疗错配修复正常（pMMR）局部晚期直肠癌（LARC）患者的1b期试验：FORTRESS研究的初步结果 Phase 1b trial of NG-350A, a CD40 agonist antibody expressing adenoviral vector, in combination with chemoradiotherapy (CRT), in patients with mismatch repair-proficient (pMMR) locally advanced rectal cancer (LARC): Initial results from the FORTRESS study Eric D. Miller, Pannaga Malalur, Sonal S. Noticewala, Arvind Dasari, Sheela Rao, Andry Santoso, Maria Hawkins, Douglas Brand, Rui Ru Ji, Korinna Pilz, Oliver Rosen
• CT156 · PDF ST316（一种同类首创的beta-catenin拮抗剂）在转移性结直肠癌（mCRC）中显示出安全性和疗效 ST316, a first in class beta-catenin antagonist, demonstrates safety and efficacy in metastatic colorectal cancer (mCRC) Anthony El-Khoueiry, Susanna V. Ulahannan, Steven Powell, Jason T. Henry, E. Gabriela Chiorean, Niharika Mettu, Zachary F. Mattes, Claudio Scuoppo, Joyce Gakuria, Franco Abbate, Jim A. Rotolo, Abi Vainstein-Haras
• CT157 · PDF MEDOCC-CrEATE试验更新：术后测量循环肿瘤DNA以指导II期结肠癌患者辅助化疗的可行性 MEDOCC-CrEATE trial update: Feasibility of measuring circulating tumor DNA post-surgery to guide adjuvant chemotherapy in stage II colon cancer patients Ingrid A. Franken, Suzanna J. Schraa, Steven L. C. Ketelaars, Carmen Rubio-Alarcón, Teunise Bisschop-Snetselaar, Bregje Adriaans, Miranda van Dongen, Linda J. W. Bosch, Mirthe Lanfermeijer, Samuel Angiuoli, Amy E. Greer, Ellen Verner, Jennifer B. Jackson, Rebecca A. Previs, Veerle M. H. Coupe, Daan van den Broek, Gerrit A. Meijer, Jill Phallen, Victor E. Velculescu, Anna J. S. van Tetering-Houben, Jeanine M. L. Roodhart, Niels F. M. Kok, Frederieke H. van der Baan, Mark Sausen, Miriam Koopman, Geraldine R. Vink, Remond J. A. Fijneman, the PLCRC-MEDOCC group
• CT158 CT158 瑞戈非尼联合avelumab治疗巨噬细胞低浸润的微卫星稳定型结直肠癌：一项前瞻性研究 Regorafenib plus avelumab in macrophage-low microsatellite-stable colorectal cancer: A prospective study Korakis Iphigenie, Sophie Cousin, Noemie Huchet, Jean-Philippe Metges, Philippe Cassier, Marc hilmi, Antoine Adenis, Antoine Hollebecque, Carine Bellera, Jean-Philippe Guegan, Alban Bessede, Antoine Italiano
• CT159 · PDF JS207（一种靶向PD-1和VEGF-A的双特异性抗体）联合JS007（抗CTLA-4）治疗晚期肝细胞癌患者的随机、多中心II期研究 JS207, a bispecific antibody targeting PD-1 and VEGF-A, combined with JS007 (anti-CTLA4), for patients with advanced hepatocellular carcinoma in a randomized, multicenter, Phase II study Jian Zhou, Guoming Shi, Yongsheng Ge, Shuijun Zhang, Xiwen Huang, Shunda Du, Yong Gao, Guohong Han, Xiaoyong Huang, Zhenda Wang, Junliang Li, Jing Xu, Jiazheng Yan, Jianjun Zou, Jia Fan
• CT160 · PDF surufatinib联合信迪利单抗和卡培他滨治疗既往经治的转移性小肠腺癌和阑尾癌的更新多中心Ib/II期分析 Updated multicenter phase Ib/II analysis of surufatinib plus sintilimab and capecitabine in previously treated metastatic small bowel adenocarcinoma and appendiceal carcinoma Xiaoyu Xie, Jianwei Zhang, Yue Cai, Xiaohui Lin, Huabin Hu, Jiayu Lin, Yan Zhang, Shanshan Li, Bohan Han, Yanhong Deng
• CT161 · PDF lurbinectedin治疗携带DNA修复突变的晚期胃肠道恶性肿瘤患者的II期临床试验 A phase II clinical trial of lurbinectedin in patients with advanced gastrointestinal malignancies with DNA repair mutations Alexa F. Viniotis, Gayle S. Jameson, Betsy C. Wertheim, Denise J. Roe, Daniel Mocan, Shelby Pearse, Sunil Sharma, Michael S. Gordon, Daniel D. Von Hoff, Erkut H. Borazanci
• CT162 · PDF VIRAGE试验中肿瘤和生物标志物应答的分析：一项随机、IIb期、开放标签研究，评估nab-紫杉醇和吉西他滨联合或不联合静脉注射VCN-01治疗转移性胰腺癌（mPDAC）患者 Analysis of tumor and biomarker responses in the VIRAGE Trial, a randomized Phase IIb, open-label, study of nab-paclitaxel and gemcitabine with/without intravenous VCN-01 in patients with metastatic pancreatic cancer (mPDAC) Rocio Garcia-Carbonero, Roberto Pazo, Teresa Macarulla, Berta Laquente, Alana Nguyen, Carmen Guillén-Ponce, Andres J. Muñoz, Edward J. Kim, Mireya Cazorla, Tara Seery, Miriam Lobo de Mena, Chris Nevala-Plagemann, Vivek R. Sharma, Eva Martinez de Castro, Charles Le, Ana Mato-Berciano, Luis A. Rojas, Carmen Blasco, Manel Cascallo, Manuel Hidalgo
• CT163 · PDF 抑制脂肪酸氧化可克服胰腺癌获得性耐药：一项II期试验已启动 Inhibiting fatty acid oxidation can overcome acquired drug resistance in pancreatic cancer: A Phase 2 trial has begun Soo-Youl Kim, Sang Woo, Wonyoung Choi, Joon Kang, Sung Sim, Jung Chun
• CT165 · PDF 使用cGMP磷酸二酯酶抑制剂改变胃癌和胃食管交界处腺癌的肿瘤微环境 Modifying the tumor microenvironment in gastric and gastroesophageal junction adenocarcinoma using a cGMP-phosphodiesterase inhibitor Junaid Arshad, Lin Ding, Palash Mallick, Mohammad Khreiss, Aaron J. Scott, Rachna Shroff, Juanita Merchant
• CT166 · PDF agenT-797、botensilimab（BOT）和balstilimab（BAL）治疗PD-1难治性胃食管癌（GEC）的II期研究 A phase II study of agenT-797, botensilimab (BOT) and balstilimab (BAL) in PD-1 refractory gastroesophageal cancer (GEC) Samuel L. Cytryn, Jeremy Tchack, Charlton Tsai, Yuval Elhanati, Patrick Evans, June Song, Michal Segal, Rory Mcgriskin, Amin Yaqubie, Joyce Lam, Haroon Kanishka, Michael B. Foote, Geoffrey Y. Ku, Steven B. Maron, Yelena Y. Janjigian

在会议检索中浏览本分会场